1. Volume 389, Issue 10069, Pages 621-628 (February 2017)
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial 
Feng-Cai Zhu, MSc, Alie H Wurie, MSc, Li-Hua Hou, PhD, Qi Liang, BS, Yu-Hua Li, PhD, James B W Russell, MD, Shi-Po Wu, PhD, Jing-Xin Li, PhD, Yue-Mei Hu, BS, Qiang Guo, PhD, Wen-Bo Xu, MD, Abdul R Wurie, MD, Wen-Juan Wang, MSc, Zhe Zhang, BS, Wen- Jiao Yin, MD, Manal Ghazzawi, BS, Xu Zhang, BS, Lei Duan, MSc, Dr Jun-Zhi Wang, PhD, Dr Wei Chen, PhD 
The Lancet 
Volume 389, Issue 10069, Pages (February 2017)
DOI: /S (16)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Reasons for exclusion listed in the appendix (p 2).
The Lancet  , DOI: ( /S (16) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2
Glycoprotein-specific antibody responses, by titres of adenovirus type-5 neutralising antibodies at baseline
(A) Low titre (≤1:200). (B) High titre (>1:200). Error bars indicate 95% CIs.
The Lancet  , DOI: ( /S (16) )
Copyright © 2017 Elsevier Ltd Terms and Conditions